Biblio

Author Title Type [ Year(Asc)]
Filters: Author is van de Donk, Niels W C J  [Clear All Filters]
2023
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, P Ho J, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2023.
van de Donk NWCJ, Minnema MC, van der Holt B, Schjesvold F, Wu KLung, Broijl A, Roeloffzen WWH, Gadisseur A, Pietrantuono G, Pour L, et al. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. Lancet Oncol. 2023.
2021
Aydin M, Tang MWai, Wondergem MJ, de Leeuw DC, Wegman JJ, Biemond BJ, van de Donk NWCJ, Zweegman S, Meijer E, Nur E. High-dose melphalan in 1 day versus over 2 days followed by autologous stem cell transplantation as consolidation treatment in patients with multiple myeloma. Br J Haematol. 2021.
2016
Zweegman S, van der Holt B, Mellqvist U-H, Salomo M, Bos GMJ, Levin M-D, Visser-Wisselaar H, Hansson M, van der Velden AWG, Deenik W, et al. Lenalidomide plus melphalan and prednisone, followed by lenalidomide maintenance versus thalidomide plus melphalan and prednisone, followed by thalidomide maintenance; results of the randomised phase 3 HOVON 87/NMSG18 trial. Blood. 2016.
Franssen LE, Raymakers RAP, Buijs A, Schmitz MF, van Dorp S, Mutis T, Lokhorst HM, van de Donk NWCJ. Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution. Eur J Haematol. 2016.
2014
Schmitz MF, Otten HG, Franssen LE, van Dorp S, Strooisma T, Lokhorst HM, van de Donk NWCJ. Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma. Haematologica. 2014.